| Autor: |
Mirjam Christ-Crain, Andrea Meienberg, Thilo Burkard, Bettina Winzeler, Fabienne Baur, Cihan Atila, Sophia Lengsfeld, Cemile Bathelt |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
BMJ Nutrition, Prevention & Health, Vol 6, Iss 2 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2516-5542 |
| DOI: |
10.1136/bmjnph-2023-000781 |
| Popis: |
Background Women seem to have more difficulty quitting smoking than men. This is particularly concerning as smoking puts women at a higher risk of developing smoking-associated diseases. Greater concerns about postcessation weight gain in women have been postulated as a possible explanation.Methods Predefined secondary analysis of a placebo-controlled, double-blind, parallel-group, superiority randomised trial including 255 adults who smoke daily (155 women, 100 men). Participants received weekly dulaglutide (1.5 mg) or placebo (0.9% sodium chloride) in addition to standardised smoking cessation care (varenicline 2 mg/day plus behavioural counselling) over 12 weeks. We aimed to investigate gender differences in weight change after dulaglutide-assisted smoking cessation. Weight change between baseline and week 12 was analysed as absolute and revative weight change and as substantial weight gain (defined as >6% increase).Results No gender differences were observed in absolute or relative weight change neither on dulaglutide nor placebo treatment. However, substantial weight gain (defined as >6% increase) in the placebo group was almost five times more frequent in females than males (24% vs 5%). Female patients were less likely to have substantial weight gain on dulaglutide compared with placebo (1% (n=1/83) vs 24% (n=17/72); p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
